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Abstract
The hyaluronic acid receptor for endocytosis (HARE; also desig-
nated Stabilin-2) mediates systemic clearance of hyaluronan and 
chondroitin sulfates from the vascular and lymphatic circulations. 
The internalized glycosaminoglycans are degraded in lysosomes, 
thus completing their normal turnover process. Sinusoidal endo-
thelial cells of human liver, lymph node, and spleen express two 
HARE isoforms of 315 and 190 kDa. Here we report that the 190- 
and 315-kDa HARE isoforms, expressed stably either in Flp-In 
293 cell lines or as soluble ectodomains, specifically bind hepa-
rin (Hep). The Kd for Hep binding to purified 190- and 315-kDa 
HARE ectodomains was 17.2 ± 4.9 and 23.4 ± 5.3 nm, respec-
tively. Cells expressing HARE readily and specifically internalized 
125I-streptavidin-biotin-Hep complexes, which was inhibited >70% 
by hyperosmolar conditions, confirming that uptake is mediated by 
the clathrin-coated pit pathway. Internalization of Hep occurred for 
many hours with an estimated HARE recycling time of ~12 min. In-
ternalized fluorescent streptavidin-biotin-Hep was present in a typ-
ical endocytic vesicular pattern and was delivered to lysosomes. 
We conclude that HARE in the sinusoidal endothelial cells of 
lymph nodes and liver likely mediates the efficient systemic clear-
ance of Hep and many different Hep-binding protein complexes 
from the lymphatic and vascular circulations. 
Abbreviations: Hep, heparin; Ab, antibody; AP, alkaline phospha-
tase; aa, amino acids; BSA, bovine serum albumin; EV, empty vector; 
GAG, glycosaminoglycan; HA, hyaluronic acid, hyaluronate, hyaluro-
nan; HARE, hyaluronan receptor for endocytosis; HS, heparan sulfate; 
HSPG, heparan sulfate proteoglycans; LDL, low density lipoprotein; 
PBS, phosphate-buffered saline; s190-HARE, soluble 190-kDa HARE 
ectodomain; s315-HARE, soluble ectodomain of the 315-kDa HARE; 
SA, streptavidin; TBS, Tris-buffered saline; 190-HARE, the 190-kDa 
HA receptor for endocytosis; 315-HARE, the 315-kDa HA receptor for 
endocytosis; b-Hep, biotin-heparin; DMEM, Dulbecco’s modified Ea-
gle’s medium; ELISA, enzyme-linked immunosorbent assay
Heparin (Hep) is the most anionic proteoglycan, due to the extensive sulfation of its glycosaminoglycan (GAG) 
chains, and contains many different sulfated disaccha-
ride isomers of N-acetylgalactosamine and glucuronic acid 
or iduronic acid. Hep binds to many different soluble, ma-
trix, and cell surface proteins and receptors, and has many 
functions, including its roles as an anti-coagulant and as a 
co-receptor for some growth factors (1, 2). Hep is a highly 
prescribed drug in surgical patients and those at risk for 
thromobosis. The genes and metabolic pathway for Hep bio-
synthesis in mast cells are understood reasonably well, and 
many of the biological and clinical activities of Hep have 
been well studied for several decades (3–6). In contrast, we 
know less about the catabolism of Hep and how total body 
homeostasis of this multifunctional proteoglycan is main-
tained. In particular, the mechanisms controlling systemic 
turnover of Hep, whether as endogenous proteoglycan or 
free chain drugs, are not known. 
Although receptors for Hep have been characterized on a 
variety of cell types (e.g. macrophages, vascular smooth mus-
cle cells), none of these mediate substantial clearance of Hep 
(7–9). A few reports implicated a role for Kupffer cells in Hep 
clearance, but were not followed up (10, 11). The possible con-
tribution of liver sinusoidal endothelial cells to Hep uptake in 
these primary cell preparations was not examined. Because 
Hep is a widely prescribed drug, it is even more important 
to understand the factors that control its clearance and, there-
fore, pharmokinetics. Animal studies of Hep clearance, except 
by renal function, have been difficult to perform, because Hep 
binds to so many soluble, cell surface or matrix proteins and 
become widely distributed after injection. 
Unfractioned Hep (3000–30000 Da), low molecular mass 
Hep (300–8000 Da), and the pentasaccharide, Fondaparinux, 
are the three classes of Hep drugs used to treat venous 
thrombosis, acute myocardial infarction, trauma, obesity, 
and coronary and peripheral vascular procedures; all situa-
tions wherein patients need immediate platelet anti-coagu-
lation therapy (12). Following an intravenous bolus, unfrac-
tioned Hep has a half-life of ~1 h and is cleared from the 
circulation by the liver and kidney (13). Low molecular mass 
Hep and the pentasaccharide, subcutaneously injected, have 
half-lives of ~3–6 and ~17 h, respectively (14). Larger more 
structurally diverse Hep is more readily cleared than the 
lower molecular weight fragments. Although clinical hand-
books declare that Hep is metabolized and cleared by the re-
ticuloendothelial system, the mechanisms for Hep clearance 
are not known. 
The primary scavenger receptor for systemic turnover 
of HA and most types of chondroitin sulfate, but not HS, is 
HARE/Stab-2, which mediates most of the total body HA 
turnover per day (15–17). HARE is found primarily in the si-
nusoidal endothelial cells of the lymph nodes, liver, and 
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spleen (18–21), and also in specialized tissues such as cor-
neal and lens epithelium, mesenchymal cells of heart valves, 
prismatic epithelial cells covering the renal papillae (17), and 
in oviduct (22). Partially degraded HA perfuses from extra-
cellular matrices in tissues and enters the lymphatic and he-
patic vascular circulation systems where it is endocytosed by 
HARE and catabolized. The partially degraded HA perfusing 
from tissues first encounters HARE in lymph nodes, which 
mediates ~85% of the daily HA turnover. The remaining 15% 
of HA drains from the lymphatics into the circulatory system 
and is removed by HARE in liver sinusoidal endothelium. 
The large full-length human HARE, encoded by the 
STAB2 gene (accession number NM_017564 on chromosome 
12q23.3 (NCBI data base), is a ~315-kDa 2551-aa glycopro-
tein (21, 23). The smaller 190-kDa HARE is not a splice vari-
ant, but rather it is an isoform derived from the full-length 
315-kDa HARE by proteolysis (23). This 190-kDa HARE is, 
in fact, a functional endocytic recycling receptor that medi-
ates GAG uptake in the absence of the larger 315-kDa HARE 
(24). A primary function of these two HARE isoforms is to 
bind and internalize HA and most of the chondroitin sulfate 
types (24–28); advanced glycation end products are also li-
gands (29, 30). The internalized HARE-ligand complexes 
traffic through the early endocytic pathway. After dissocia-
tion, the receptor recycles back to the cell surface, whereas 
the GAG ligand is delivered to lysosomes for degradation 
(19, 24, 30, 31). 
In this report, we identify HARE as the receptor that spe-
cifically binds, internalizes, and mediates degradation of 
Hep. We demonstrate specific and high affinity HARE-Hep 
binding under a variety of conditions and active HARE-me-
diated endocytosis of Hep in stable cell lines. We conclude 
that Hep clearance by the body is mediated, probably pre-
dominantly, by HARE in the sinusoidal endothelium of the 
liver and lymph nodes. 
Experimental Procedures
Materials, Solutions, and Buffers—Hep (free chains) was 
from Celsus (Cincinnati, OH) and Sigma. Flp-In 293 cells, fe-
tal bovine serum, high glucose Dulbecco’s modified Eagle’s 
medium (DMEM), hygromycin B, Zeocin, glutamine, plas-
mid expression vectors, super-competent TOP10 Escherichia 
coli, LysoTracker DND-99, SA-Alexa 488, and Lipofectamine 
2000 were from Invitrogen. 125Iodine (100 mCi/ml; specific 
activity of >0.6 TBq/mg) in NaOH and Sepharose 6 Fast 
Flow (nickel-nitrilotriacetic acid) resin were from GE Health-
care. PolySorP strips were from Nalgene Nunc, Int. (Roch-
ester, NY). EpranEx plates were from Plasso, LLC (UK). 
Streptavidin (SA) was from Pierce. 125I-SA was prepared as 
described previously (32, 33). The protocol of Yu and Toole 
(34) was used to make biotin-Hep (b-Hep), and the number 
of biotins/chain was quantified using a QuantTag™ Biotin 
Kit (Vector Labs, Burlingame, CA). Size exclusion multian-
gle laser light scattering was performed to measure Hep mo-
lar mass and concentration, and to verify the addition of 1–2 
biotins per Hep chain, without degradation (23). Western 
blot analysis was by colorimetric or enhanced chemilumines-
cence detection of blotted protein. Other materials, reagents, 
and kits were obtained as described recently (23). TBS con-
tains 20 mm Tris-HCl, pH 7.0, 150 mm NaCl; TBST is TBS 
with 0.1% Tween 20. TBST/BSA is TBST with 1.0% (w/v) 
BSA. Coating Buffer for ELISA contains 15 mm Na2CO3, 36 
mm NaHCO3, pH 9.5. PBS contains 137 mm NaCl, 8 mm 
Na2HPO4, 1.5 mm KH2PO4, 2.7 mm KCl, pH 7.2. Hanks’ bal-
anced salts solution contains 5 mm KCl, 0.4 mm KH2PO4, 0.8 
mm MgSO4, 137 mm NaCl, 0.3 mm Na2HPO4, 5.5 mm glu-
cose, 1.26 mm CaCl2, 0.5 mm MgCl2, and 28 μm phenol red; 
at the time of use, 3.5 g/100 ml of NaHCO3 was added and 
the pH was adjusted to 7.2 with HCl. Endocytosis medium 
contains DMEM with 0.05% BSA. 
Constructs and Cell Lines Expressing Membrane-anchored or 
Soluble 190-HARE, 190-HARE(ΔLink), or 315-HARE—Prep-
aration of cDNA constructs and vectors for the creation of 
stably transfected 293 Flp-In cell lines expressing, the full-
length 315-HARE, 190-HARE, or the secreted ectodomains 
of the 315-HARE or 190-HARE (lacking transmembrane and 
cytoplasmic domains) were described by Harris et al. (23, 24). 
Creation of 190-HARE(ΔLink) cDNA constructs and stable 
cell lines was described recently (35). All recombinant HARE 
proteins contain C-terminal V5 and His6 epitope tags. Fi-
nal clones were selected based on criteria of normal growth 
and morphology, good HARE expression, and that a single 
cDNA had inserted at the recombinase-mediated integration 
site provided in the Flp-In cell lines. SDS-PAGE using 5% 
gels and Western analysis using anti-V5 Ab were performed 
as described (24). 
Preparation of 125I-SA·b-Hep Complexes—For cell-based as-
says, 2:1 molar ratios of b-Hep and 125I-SA were mixed, at 40–
50-fold higher concentrations than in experiments, in 0.5 ml 
of Endocytosis medium for 30 min on a rotary mixer at room 
temperature just prior to an experiment. For controls with 125I-
SA alone, the same proportional amounts of free biotin and 
125I-SA were used. After mixing, the 125I-SA·b-Hep or 125I-
SA·biotin complexes were diluted into Endocytosis medium. 
Final concentrations of b-Hep and 125I-SA complexes in assays 
were 100 and 96 nm (2.5 μg/ml), respectively. 
Binding and Endocytosis of 125I-SA·b-Hep—Stably trans-
fected cells, clone 9 (24), expressing 190-kDa HARE, were 
plated in 12-well dishes and grown in DMEM with 8% fetal 
calf serum and 100 μg/ml hygromycin B for at least 2 days 
prior to experiments. Cells were washed with Hanks’ bal-
anced salt solution and incubated at 37 °C for 60 min with 
Endocytosis medium (no serum) to allow HARE-mediated 
internalization of any bound serum GAGs. Endocytosis as-
says with these washed cells were performed at 37 °C in En-
docytosis medium containing pre-formed complexes of 125I-
SA·b-Hep with or without unlabeled Hep as competitor. 
Binding of 125I-SA·b-Hep to cells was measured at 4 °C. Spe-
cific binding or endocytosis was assessed in the presence of 
excess unlabeled Hep and, in most cases, in cells incubated 
in parallel with only 125I-SA-biotin to determine background 
counts/min values. These values were subtracted from all 
data points to determine specific 125I-SA·b-Hep endocyto-
sis. To determine the amount of 125I-SA·b-Hep binding by 
the total cell HARE population, cells on ice were permeabi-
lized with 0.055% (w/v) digitonin, using a 25% stock solu-
tion dissolved in anhydrous dimethyl sulfoxide (36). At the 
indicated times, cells were washed three times with ice-cold 
Hanks’ balanced salt solution, lysed in 0.3 n NaOH, and ra-
dioactivity and protein content (37) were determined and ex-
pressed as counts/min/μg of protein. 
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Ligand Blot Assay for b-Hep Binding—Cells expressing 
315- or 190-HARE were scraped from T-75 flasks in the 
presence of serum and lysed in 0.5% Nonidet P-40. After 
rotating for 1 h at 24 °C, cell debris was removed by centrif-
ugation, and the cell lysate was immunoprecipitated with 
anti-V5 Ab, which recognizes this fusion epitope on both 
recombinant proteins. Following 5% SDS-PAGE, the pro-
teins were transferred to nitrocellulose membranes and 
blocked with TBST, 1% BSA at 4 °C for 2 h. The method 
for detecting b-Hep binding to HARE is a modification of 
a ligand blot procedure for HA binding (38). Nitrocellulose 
membranes were incubated with TBST/BSA for 2 h at 4 °C, 
washed, and incubated with 200 nm b-Hep in TBST/BSA, 
with or without 2000 nm unlabeled Hep as competitor to 
assess nonspecific binding. After incubation for 1.5 h at 4 
°C, the membrane was washed with excess TBST at least 5 
times over 30 min, and incubated with 2.0 μg/ml 125I-SA 
for 30 min. After washing with TBST at least 5 times over 
30 min, the membrane was dried at 22 °C and bound 125I-
SA was detected by autoradiography using Kodak MS film 
exposed at -80 °C for 1–18 h. 
Western Blot Analysis—Following the ligand blot proce-
dure, the membranes were rehydrated in TBST/BSA, incu-
bated with 20 ng/ml anti-V5 Ab (Bethyl Labs, Montgomery, 
TX), washed, incubated with the appropriate secondary Ab 
conjugated with horseradish peroxidase, and detected by 
ECL. The ECL signal was captured using Classic Blue Film 
BX (MIDSCI, St. Louis, MO). Densitometry on both the West-
ern and ligand blot films was performed with an Alpha In-
notech FluorChem 8000. 
Fluorescence Microscopy—Cells were grown on 18-mm 
glass coverslips in complete medium for at least 2 days prior 
to the experiment. B-Hep (100 nm) or unlabeled Hep was 
combined with 1 μg/ml SA-Alexa 488 in 0.5 ml of DMEM 
and rotated for 30 min prior to the experiment. Live cells 
were incubated with SA-Alexa 488·(biotin)-Hep conjugates 
in Endocytosis medium for 6 h at 37 °C. The medium was 
replaced with fresh Endocytosis medium containing 50 nm 
LysoTracker and the cells were incubated for 1 h. Live cells 
on glass coverslips were washed by dipping slides into PBS 
3 times and immediately mounted onto glass slides prior to 
visualization using a Nikon Diaphot 300 fluorescence micro-
scope. Images were captured with a DXM1200 side-mounted 
camera operated by Act-1 software version 2.6.3. 
sHARE Purification—s190-HARE and s315-HARE were 
purified from pooled growth media by Ni2+ chelate affin-
ity chromatography, followed by SDS-PAGE and electroelu-
tion as described by Harris et al. (24). Final purified HARE 
preparations were concentrated to 0.1–1.0 mg/ml using Am-
icon concentrators (Millipore), washed twice with PBS, and 
stored at -20 °C until use in subsequent assays. 
ELISA-like—A set amount of HARE protein in Coating 
Buffer (200 μl) was placed in each well of a PolySorP strip, 
sealed to prevent evaporation, and incubated overnight at 
room temperature. All subsequent steps were carried out at 
37 °C. The surfaces of the wells were then blocked by incuba-
tion with TBST and 2% BSA for 1.5 h. After washing, increas-
ing concentrations of b-Hep were added and the plates were 
incubated for 2 h, washed 6 times with TBST, incubated for 
1 h with SA-AP, washed 6 times in TBST, and finally incu-
bated with p-nitrophenol phosphate. The A405 values of the 
strips were determined every 15 min for 1 h using a Spectra-
Max 340 (Molecular Devices) plate reader. 
Biotinylation and Iodination of BSA—BSA (2 mg) was bio-
tinylated using Sulfo-NHS-LC-biotin (Pierce) according to 
the manufacturer’s instructions and then dialyzed exten-
sively against PBS to eliminate excess free biotin. A 10:1 mo-
lar ratio of biotin-to-BSA molecules was used and the final 
b-BSA product contained an average of 5 biotins/BSA (a 
50% efficient reaction), as assessed with the QuantTag Bio-
tin Kit (Vector Labs). B-BSA (0.4 mg) was then iodinated as 
described previously using 0.5 mCi of 125I for 15 min at 22 
°C (39). 125I-b-BSA was separated from free iodine on a PD-
10 column, and 0.5-ml fractions were collected and assessed 
for radioactivity using a γ-counter. Fractions in the first void 
volume peak were pooled, and protein content and radioac-
tivity were determined. 
Degradation Assay—190-HARE and EV cells were 
grown to 80–90% confluence in 12-well plates prior to ex-
periments. In initial trials, ternary complexes of 125I-b-
BSA·SA·b-Hep were formed using numerous ratios of the 
three components, and then tested for specific endocytosis 
by 190-HARE cells. These results indicated an optimal ratio 
of 100 nm 125I-b-BSA, 200 nm SA, and 100 nm b-Hep. The 
ternary complexes were allowed to form while mixing by 
rotation at room temperature for 2 h just prior to an exper-
iment. Similar mixtures containing 125I-b-BSA and b-Hep 
without the SA linker or the ternary complexes with a 100-
fold excess of unlabeled Hep were used as controls for non-
specific endocytosis. One hour prior to an experiment, cells 
were incubated in DMEM containing 2% BSA to block non-
specific binding sites and to allow endocytosis of any se-
rum-derived GAGs bound to cell surface HARE. Cells were 
then incubated in DMEM/BSA with 0.5 ml of the ternary 
complexes or the control mixtures for 4 h, washed 3 times 
with 2 ml of cold Hanks’ balanced salt solution, and incu-
bated for 15 h in 0.5 ml of fresh DMEM plus 2% serum. The 
collected chase medium was cleared of cell debris by cen-
trifugation and loaded on a PD-10 (G-25 Sephadex) column 
and eluted with PBS. Forty-eight 0.5-ml fractions were col-
lected and radioactivity in each fraction was determined 
using a γ-counter. 
Results
The possibility that HARE is the major systemic clearance 
receptor for Hep in the vascular and lymphatic circulatory 
systems has great physiological significance and would be 
an important finding. We, therefore, sought to test this using 
a variety of protein- and cell-based assays. 
The Purified s315- and s190-HARE Ectodomains Bind B-
Hep—To determine whether Hep can bind to both HARE 
isoforms, we used direct ELISA-like binding assays with 
the purified recombinant 190-HARE and 315-HARE ectodo-
mains. As the b-Hep concentration increased, the amount of 
b-Hep bound to s190-HARE increased sharply and saturated 
above ~100 nm (Figure 1A, solid line). These data were read-
ily fit by nonlinear regression analysis to a hyperbolic bind-
ing curve, indicating a single class of Hep binding sites with 
a Kd of 17.4 ± 4.9 nm (p < 0.0001). Binding of b-Hep was spe-
cific, because the presence of excess unlabeled Hep elimi-
nated by >95% the binding of SA-AP (not shown). A similar 
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experiment with the 315-HARE ectodomain also showed a 
hyperbolic binding curve for b-Hep (Figure 1A, dashed line) 
with a Kd of 23.2 ± 5.3 nm (p < 0.0001), indicating virtually 
identical binding kinetics for the s190- and s315-HARE pro-
teins. Thus, the additional N-terminal portion of the s315-
HARE, consisting of 1135 aa, is not involved in Hep binding. 
The results confirm that Hep specifically binds with high af-
finity to the purified s190-HARE and s315-HARE ectodo-
mains in vitro. 
A “Reverse” ELISA-like Assay Validates the Specific HARE-
Hep Interaction—To ensure that the biotin tag was not pro-
ducing false positive signals in our in vitro and endocyto-
sis assays, we assessed specific Hep binding using a reverse 
ELISA-like assay. Unlabeled Hep was coated onto EpranEx 
plates according to the manufacturer’s instructions and then 
allowed to bind with purified s190-HARE protein. Primary 
anti-V5 Ab, directed against the HARE C-terminal epitope 
tag, followed by a secondary Ab-AP conjugate, was used to 
detect HARE binding with Hep (Figure 1B). Because Hep is 
highly anionic, and sticks nonspecifically to many proteins, 
we included controls to ensure that the primary (1′) or sec-
ondary (2′) Abs were not randomly adhering to Hep or to 
the plastic. All controls showed about the same low values 
(~10% of maximum), indicating that the signal output from 
this assay is not due to nonspecific Hep binding. This assay 
also validates results from the ligand blot and endocytosis 
assays that use pre-formed 125I-SA·b-Hep complexes. 
The Membrane-anchored 315- and 190-HARE Proteins Bind 
B-Hep—The ability of the intact 190-HARE and 315-HARE 
isoforms to bind Hep was assessed in membrane extracts af-
ter nonreducing SDS-PAGE and transfer to nitrocellulose. 
The HARE proteins re-nature after electrotransfer and incu-
bation with Tween 20, and can be detected by a ligand blot 
assay with 125I-HA (38). Nitrocellulose strips containing 190-
HARE or 315-HARE were incubated with b-Hep (Figure 2), 
with or without an excess of unlabeled Hep, to determine 
nonspecific binding, and b-Hep binding was assessed using 
125I-SA and autoradiography. The results show that b-Hep 
binds to both HARE membrane proteins and binding is in-
hibited ≥95% by unlabeled Hep. 
Cells Expressing 190-HARE Specifically Endocytose Hep—Be-
cause it is difficult to radioiodinate Hep without substantial 
modification, we developed a protocol to measure binding or 
internalization using 125I-SA complexed to b-Hep. Pre-formed 
125I-SA·b-Hep complexes (using an optimum 2:1 molar ra-
tio of SA:b-Hep) are readily taken up by cell lines express-
ing the 190-HARE alone (Figure 3A, circles). The rate of Hep 
endocytosis was linear for 8 h and then plateaued, indicat-
ing a steady-state accumulation of ligand. Because Hep nat-
urally “sticks” to many substances, specific HARE-mediated 
Figure 1. Hep binding to the purified ectodomains of 190-kDa and 
315-kDa HARE is specific. A, equal molar amounts of purified s190- 
(○) and s315-HARE (•) proteins were coated onto PolySorP strips. 
Strips were blocked with 2% BSA to prevent nonspecific binding, 
washed, and incubated with 1.0–1024 nm b-Hep for 1.5 h as indicated. 
Bound b-Hep was detected with SA-AP and lines were calculated by 
regression analysis (SigmaPlot version 10). The Kd for b-Hep binding 
to s190-HARE (solid line) was 17.4 ± 4.9 nm (p < 0.0001) and the Kd 
for b-Hep binding to s315-HARE (dotted line) was 23.2 ± 5.3 nm (p < 
0.0001). B, unlabeled Hep was coated onto EpranEx plates according 
to the manufacturer’s instructions (black bars). Purified s190-HARE (4 
μg/ml) was incubated in each well (except as indicated) for 2 h at 37 
°C. Bound s190-HARE was detected with primary (1′ Ab) anti-V5 Ab 
(+) or buffer only (-) and after washing, the wells were treated with buf-
fer (-) or secondary (2′ Ab) anti-goat Ab-AP conjugate (+) as indicated. 
Values are the mean ± S.E. (n = 3) A405. 
Figure 2. Hep binds specifically to the 190-HARE and 315-HARE 
membrane proteins. 190- and 315-kDa HARE proteins from cell ly-
sates were immunoprecipitated with anti-V5 Ab, separated on 5% 
SDS-PAGE, and electrotransferred to nitrocellulose. For the ligand blot 
(LB), strips of nitrocellulose were incubated with 200 nm b-Hep with or 
without unlabeled excess (Xs) Hep, and b-Hep binding was detected 
with 125I-SA followed by autoradiography. Western blot (WB) analysis 
was then performed on the same blot using anti-V5 Ab to identify both 
isoforms of HARE followed by ECL detection. 
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internalization of 125I-SA·b-Hep into cells was assessed 
with three controls. First, the parent cell line expressing the 
empty vector (EV) was incubated with 125I-SA·b-Hep to de-
termine whether any other native receptor on the cell sur-
face was able to bind and internalize Hep (Figure 3A, trian-
gles). Second, a 10-fold molar excess of Hep was added to 
HARE-expressing cells incubated with 125I-SA·b-Hep to de-
termine the specificity of Hep binding to HARE (≥90%; not 
shown). Third, under the same experimental conditions in 
parallel, both EV and HARE expressing cells were incubated 
with 125I-SA-biotin (without Hep) to verify that the radioac-
tive signal with 125I-SA·b-Hep was a function of HARE-b-
Hep interactions and not nonspecific binding by either biotin 
or 125I-SA to the cells (not shown). All three above controls 
to assess nonspecific endocytosis of 125I-SA-biotin were low 
(≤5%) and virtually identical for both cell lines. 
The HARE Link Domain Is Required for HA, but Not Hep, 
Endocytosis—Because we recently showed that the Link do-
main of HARE is required for HA binding (35), we wanted 
to determine whether it was also needed for Hep endocy-
tosis. Using PCR-based techniques, we made a 190-HARE 
mutant lacking the 93-amino acid Link domain and cre-
ated stable 190-HARE(ΔLink) cell lines. To compare the 
Hep uptake abilities of 190-HARE(ΔLink) and wild type 
190-HARE, we incubated both types of cells with either 125I-
SA·b-HA or 125I-SA·b-Hep (Figure 3B). Nonspecific endo-
cytosis of 125I-SA-biotin was subtracted to assess specific 
internalization of HA or Hep by both cell lines. Cells ex-
pressing the 190-HARE (Figure 3B, black bars) internalized 
both b-HA and b-Hep complexes, as expected. In contrast, 
cells expressing 190-HARE(ΔLink) (Figure 3B, gray bars) in-
ternalized a similar amount of b-Hep, but very little b-HA. 
These results confirm, for the first time, that the HARE 
Link domain is necessary for HA, but not Hep, binding and 
internalization. 
190-kDa HARE Is a Recycling Endocytic Receptor for Hep 
Internalization—HA uptake involves binding to HARE, in-
ternalization, and then dissociation in maturing acidic en-
dosomes. The “free” receptor is recycled back to the cell 
surface and undergoes multiple rounds of HA internaliza-
tion. We used 190-HARE and EV cells to compare cell sur-
face binding versus cellular accumulation of Hep to deter-
mine whether HARE also is able to release Hep and recycle 
back to the cell surface to bind and internalize more Hep 
in a continuous manner (Figure 4A). At 4 °C Hep binds to 
190-HARE on the cell surface, which comprises ~10% of the 
total cellular receptor number (23, 24). To assess receptor 
recycling, we compared values for surface binding to Hep 
(i.e. number of surface Hep receptors) with total cellular ac-
cumulation of Hep by endocytosis at 37 °C over 3 h. After 
subtracting the nonspecific values for both cell lines, 190-
HARE cells internalized ~15 times the amount of total Hep 
compared with the surface-bound Hep. We estimate that 
the receptor recycling time is ~12 min: to bind, internalize, 
and release Hep, and then return to the cell surface for an-
other endocytic cycle. 
Hep Endocytosis Is Mediated by the Clathrin-coated Pit 
Pathway—The clathrin-coated pit pathway is one of the 
most efficient and rapid methods employed by cells to in-
ternalize ligands. Endocytosis via the clathrin-coated path-
way can be temporarily and reversibly inhibited by hyper-
osmolar conditions, e.g. ≥400 mm sucrose as an osmolite 
(40–42). Because, our previous data show that HARE uti-
lizes this pathway for internalization of HA (23, 24, 31), 
our goal was to determine whether HARE retains this 
property when bound with Hep. Cells expressing 190-
HARE were incubated with 125I-SA·b-Hep in DMEM, with 
increasing concentrations of sucrose, or with non-labeled 
Hep as competitor for 4 h (Figure 4B). Under hyperosmotic 
conditions (e.g. ≥0.4 m sucrose), specific receptor-mediated 
endocytosis of 125I-SA·b-Hep decreased by >70%, indicat-
ing that Hep uptake depends on clathrin assembly into 
coated pits. Cells incubated with 125I-SA·b-Hep and excess 
unlabeled Hep represented the nonspecific baseline (~10%) 
for Hep binding and internalization. In conclusion, these 
data demonstrate that the internalization of Hep is depen-
dent on the receptor (HARE)-mediated clathrin-coated pit 
pathway. 
Figure 3. Endocytosis of Hep by cells expressing recombinant 190-
HARE. A, two independent human 190-HARE cell lines (●, ○) and EV 
cells (▲) were grown to ≥80% confluence, washed, and incubated in 
Endocytosis medium for 1 h to clear receptors of any serum-derived 
GAGs. To measure endocytosis, cells were incubated with 2.5 μg/ml 
pre-formed complexes of 125I-SA·b-Hep or 125I-SA-biotin alone in En-
docytosis medium for the indicated times. Values are the mean ± S.E. 
(n = 3) of specific cell-associated counts/min/μg of cell lysate protein. 
The average nonspecific cell-associated 125I-SA-biotin was essen-
tially the same (≤5%) in all cell lines and was subtracted from the to-
tal to obtain the sample values shown. B, 190-HARE (black bars) and 
190-HARE(ΔLink) (gray bars) cells were allowed to internalize either 
125I-SA·b-HA or 125I-SA·b-Hep at 37 °C for 4 h in parallel with the non-
specific 125I-SA-biotin controls. Cells were processed and values pre-
sented as above in A. 
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Internalized Hep Is Delivered to Lysosomes—Previous stud-
ies with both the rat and human HARE isoforms showed 
that HARE binds, internalizes, and delivers HA to lysosomes 
(19, 24, 31). To confirm that Hep is also internalized and de-
livered to lysosomes, we incubated 190-HARE cells with SA-
Alexa 488 bound to b-Hep or free in the presence of unla-
beled Hep, as a negative control (Figure 5). After 6 h, the 
medium was replaced with medium containing 50 nm Ly-
soTracker (Invitrogen), a non-toxic, membrane-permeable, 
weakly basic dye, which is fluorescent when protonated in 
acidic compartments (e.g. lysosomes). Lower magnification 
shows a fairly homogenous population of cells expressing 
HARE (Figure 5). It is evident that 190-HARE cells have nu-
merous lysosomes, as indicated by LysoTracker (Figure 5, 
A, C, and E). SA-Alexa 488-b-Hep was also present in many 
internal vesicles, some of which also stained with the Lyso-
Tracker dye (Figure 5, D and F). This is expected, because 
many compartments along the intracellular endocytic path-
way become saturated relatively quickly with the internal-
ized Hep and then wait to be delivered to lysosomes, where 
the slower degradation processes occur. To ensure that fluo-
rescence was not due to nonspecific internalization of SA-Al-
exa 488, cells were incubated with the same amount of SA-
Alexa 488 and unlabeled Hep. By uncoupling the Hep from 
the fluorescent tag, the cells could be assessed for nonspecific 
endocytosis of SA-Alexa 488. Most cells internalized a tiny 
amount of SA-Alexa 488, as expected, but overall cell fluo-
rescence decreased >95% and was difficult to capture, even 
at a higher camera sensitivity (Figure 5B). Thus, the vast ma-
jority of the SA-Alexa 488·b-Hep conjugate is internalized 
specifically via HARE (Figure 5, D and F). 
Degradation of internalized b-Hep is difficult to demon-
strate directly, because all cells have other biotin-containing 
molecules. Therefore, we verified that b-Hep is degraded af-
ter endocytosis by an indirect approach using ternary com-
plexes of 125I-b-BSA·SA·b-Hep (Figure 6). 125I-SA·b-Hep 
could not be used, because SA is extremely resistant to prote-
ases after uptake by cells or in vitro (e.g. treatment of 125I-SA 
Figure 4. HARE mediates specific continuous clathrin-dependent en-
docytosis of Hep. 190-HARE cells and EV cells were grown and pre-
pared as described in the legend to Figure 3. A, preformed 125I-SA·b-
Hep complexes in Endocytosis medium were added and 190-HARE 
and EV cells were incubated for 3 h at either 37 (endocytosis, black 
bars) or 4 °C (cell surface binding, gray bars). Cells were then washed, 
lysed, and radioactivity and protein content determined. B, to test the 
effect of hyperosmolarity on endocytosis, cells were preincubated in 
either isosmotic or hyperosmotic (with 0.2 or 0.4 m sucrose) Endocyto-
sis medium for 15 min, and then incubated for 4 h with 125I-SA·b-Hep 
in isosmotic (black bar) or hyperosmotic (gray bars) conditions or isos-
motic conditions with excess unlabeled Hep (white bars) as a nonspe-
cific internalization control. Values are the mean ± S.E. (n = 3) cell-as-
sociated specific counts/min/μg of protein. 
Figure 5. Cells expressing 190-HARE deliver internalized Hep to lyso-
somes. 190-HARE cells were incubated for 6 h with SA-Alexa 488 in 
the presence of unlabeled Hep (A and B) or SA-Alexa 488 bound to b-
Hep (C–F). Live cells were visualized at ×200 magnification (A–D) or 
×400 magnification (E and F) as described under “Experimental Pro-
cedures.” Cell images were captured in two different color channels: 
LysoTracker-containing vesicles (A, C, and E) were visualized in the 
red channel, whereas SA-Alexa 488 in the presence of unlabeled Hep 
(B) or bound to b-Hep (D and F) was visualized in the green chan-
nel. The white arrows point to red lysosomes that are also loaded (and 
likely co-localized) with green SA-Alexa 488·b-Hep. In contrast, the 
yellow arrows indicate vesicles containing SA-Alexa 488·b-Hep that 
are not acidic (E and F). Cells expressing EV did not internalize SA-Al-
exa 488·b-Hep (not shown). 
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with pronase, trypsin or proteinase K for 2 h at 37 °C did not 
alter band intensity or position; by SDS-PAGE, silver stain-
ing, and autoradiography). In contrast, BSA was 100% de-
graded under the same conditions (not shown). 
To assess degradation, we used ternary complexes of 
125I-b-BSA·SA·b-Hep in an indirect approach in which bio-
tin-BSA is degraded only following Hep-mediated endo-
cytosis (Figure 6). Complexes of 125I-b-BSA·SA·b-Hep were 
formed under conditions that optimized specific Hep-de-
pendent endocytosis by 190-HARE cells. 190-HARE or EV 
cells were incubated with these ternary (or other control) 
complexes for 4 h to load up intracellular endocytic vesi-
cles and then chased for 15 h with fresh medium to allow 
time for delivery to lysosomes, degradation, and release of 
degradation products. Gel filtration of 125I-b-BSA·SA·b-Hep 
chase medium samples showed most of the 125I-labeled ra-
dioactivity in the included second peak, indicating that lyso-
somal enzymes had digested 125I-BSA to a variety of smaller 
sizes (Figure 6A). A small amount of radioactivity was pres-
ent in the void volume; probably partially digested or undi-
gested complexes. 125I-b-BSA degradation products were vir-
tually absent in the EV cell control, indicating that cells not 
expressing HARE do not internalize Hep, and thus do not 
degrade 125I-b-BSA·SA·b-Hep complexes (Figure 6D). To en-
sure that the 125I-b-BSA·SA·b-Hep degradation peak was the 
result of Hep-mediated endocytosis, 190-HARE cells were 
incubated with these complexes in the presence of a 100-fold 
excess of Hep (Figure 6B). The amount of degraded products 
decreased by 96% (after subtracting the small EV cell back-
ground), confirming that HARE is required for the observed 
degradation. As a second control, 190-HARE cells were in-
cubated with “uncoupled” complexes (i.e. 125I-b-BSA and 
b-Hep) to which SA was not added to connect b-Hep with 
125I-b-BSA (Figure 6C). Again, degradation of 125I-b-BSA 
was decreased 81%, consistent with the conclusion that 125I-
b-BSA·SA·b-Hep internalization requires HARE-mediated 
binding to Hep. 
Discussion
HARE (also designated Stabilin-2 and Feel-2) is the pri-
mary receptor for the clearance of many GAGs from the cir-
culatory and lymphatic systems. HARE is a recycling recep-
tor that operates via the coated pit endocytosis pathway to 
mediate internalization, and the subsequent delivery of li-
gand to lysosomes for degradation (19, 23, 24, 31, 43). Full-
length 315-kDa HARE is a type I membrane protein (2551 
aa) with a small cytoplasmic domain (72 aa), one mem-
brane domain, and a large extracellular domain (2458 aa). 
The 190-kDa HARE is identical to the C-terminal 1417 aa of 
the 315-HARE, and is generated in vivo and in vitro in sta-
Figure 6. Hep·BSA complexes are degraded after HARE-mediated 
endocytosis. To assess the HARE and Hep dependence of degrada-
tion, the following combinations of cell type and 125I-b-BSA complexes 
were used: 190-HARE cells were incubated with 125I-b-BSA·SA·b-Hep 
complexes without (A) or with (B) a 100-fold excess of unlabeled Hep, 
or with 125I-b-BSA and b-Hep in the absence of SA (C), EV cells (D) 
were incubated with 125I-b-BSA·SA·b-Hep complexes. Cells were in-
cubated at 37 °C for 4 h, washed, and then incubated for 15 h with 
fresh medium. Medium samples were chromatographed over PD-10 
columns and 0.5-ml fractions were assessed for radioactivity. The first 
peak (V0; fraction 10) represents a small amount of intact 
125I-b-BSA, 
coupled or uncoupled to SA·b-Hep. The large broad peak (fractions 
20–45) represents degraded 125I-b-BSA fragments that were released 
into the medium, after lysosomal digestion, during the chase period. 
Data points are the average of three separate samples. 
17348 Harris, Weigel, & Weigel  in Journal of Biological chemistry  283 (2008) 
bly transfected cells by proteolytic cleavage (19, 24). We and 
others report that recombinant HARE behaves similarly in in 
vitro cell culture and in the sinusoidal endothelium of liver, 
lymph node, and spleen (28, 30, 44, 72). We show in this re-
port that purified s190-HARE ectodomain specifically binds 
Hep (Figures 1 and 2), that cells expressing the recombinant 
protein internalize labeled Hep (Figures 3 and 4), and that 
Hep is trafficked to lysosomes (Figures 5 and 6). 
This is the first report that HARE is also involved in the 
systemic clearance and homeostasis of Hep. For several de-
cades, the anticoagulant properties of Hep have been used 
to treat thrombosis. However, newly recognized Hep prop-
erties may be useful as inhibitors of cancer metastasis and 
HIV-1 replication (45, 46). As with any soluble circulating 
factor designed to stimulate cellular responses, there must be 
efficient (and often redundant) mechanisms to dampen the 
signal and restore normal homeostasis. Despite thousands 
of basic and clinical studies on the biology of Hep, few re-
ports have implicated specific receptors or cell types that are 
involved in the important process of removing Hep quickly 
and efficiently after its biological actions have been initiated. 
In contrast to HA, little is known about the systemic turn-
over of Hep, although a current model is that extracellu-
lar heparanases and proteases partially degrade Hep and 
HSPGs, and the released GAG fragments could then be in-
ternalized and completely degraded at the local tissue level 
(47). Extracellular matrix and intracellular heparanases are 
important for HSPG turnover, Hep catabolism, and extra-
cellular matrix remodeling (47–51). During extracellular ma-
trix remodeling, a majority of the resulting free GAGs and 
proteoglycan fragments enter the lymphatic and circulatory 
systems, especially during injury or disease. Without an ef-
ficient GAG-clearing mechanism, these fluid circulatory sys-
tems would be overwhelmed with large amounts of debris 
derived from tissue extracellular matrixes throughout the 
body. We propose that the scavenger receptor HARE in si-
nusoidal endothelial cells of liver and lymph node, and per-
haps spleen, recognizes and internalizes Hep for eventual 
degradation in lysosomes. 
The liver is a primary organ for Hep homeostasis involv-
ing Hep-binding activities in the sinusoidal or non-continu-
ous endothelium (52), Kupffer cells (10), and parenchymal 
cells (53). All these cell types contain scavenger receptors 
such as SCARB1 on parenchymal cells (54, 55) and macro-
sialin (56) and LOX-1 (57) on Kupffer cells. HARE is found 
in sinusoidal endothelial cells, not in Kupffer or parenchy-
mal cells. HARE is also one of the few scavenger receptors 
identified to be associated with clathrin-coated pits (19, 30, 
31), which contributes to much higher endocytosis and recy-
cling rates (e.g. Figure 4B). In the past 20 years, many scaven-
ger receptors have been cloned and, by definition, their com-
mon ligands are LDL or its derivatives, acetylated LDL and 
oxidized LDL (58). Scavenger receptors often bind more than 
one ligand and some (e.g. macrosialin and Lox-1) bind Hep, 
whereas MARCO, SREC, and CL-PI do not (58). HARE, like 
other scavenger receptors, binds acetylated LDL (E. N. Har-
ris and P. H. Weigel, unpublished results, 29, 59). Despite 
much accumulated ligand binding data on these scavenger 
receptors, Hep binding has been assessed only as a competi-
tor for binding of LDL, acetylated LDL, or oxidized LDL; la-
beled Hep was not used in direct binding studies. Negative 
results in indirect binding studies do not exclude the possi-
bility that Hep binds to other independent sites on MARCO, 
SREC, and CL-PI. This is the first report to show directly that 
Hep binds with high affinity to both purified recombinant 
HARE in vitro and to live cells expressing HARE. 
Thus far, direct binding studies have shown that HARE 
binds with HA (18), advanced glycation end products (29), 
several chondroitin sulfates (23), and Hep (this study). In ad-
dition, HARE is expressed in prime locations (e.g. the endo-
thelium of liver and lymph nodes) to be a front-line receptor 
able to internalize multiple ligands. Hep binding to vascu-
lar endothelium after intravenous injection into animals 
was first reported by Mahadoo et al. (60). Follow-up stud-
ies showed Hep binding and endocytosis by cultured vascu-
lar endothelial cells, but no receptor was ever identified (61, 
62). Moreover, these studies were from the perspective of 
how Hep binding to vascular endothelium affected soluble 
protein mediators in the coagulation cascade, and they con-
cluded that the vascular endothelium is involved with par-
tial neutralization of the anticoagulant activity of Hep. Both 
groups concluded that Hep binding sites on the vascular en-
dothelium were nonspecific. 
In contrast, the present study shows that both isoforms 
of HARE specifically bind Hep with high affinity and medi-
ate its rapid internalization. Because HARE is a continuously 
recycling receptor, it clears Hep very efficiently. The esti-
mated recycling time for HARE-mediated uptake of Hep is 
very similar to the values for HARE-mediated uptake of HA 
(31) and those for the asialoglycoprotein (43), mannose (63), 
transferrin (64), and LDL (65) receptors. 
Because HA and Hep are both natural ligands for HARE, 
an important question is do they compete with each other 
for binding. Data from ongoing studies, show that HA and 
Hep do not compete with each other, consistent with reports 
using labeled Hep and HA in animals (E. N. Harris and P. H. 
Weigel, unpublished results, 66, 67). Unlabeled HA or chon-
droitin sulfate did not affect clearance of labeled Hep, in-
dicating the binding sites for Hep were not the same as for 
HA. Liver sinusoidal endothelial cells have two active but 
different binding activities for HA and Hep, and the natu-
ral assumption was that two different receptors must be in-
volved. In the present report we show that, in fact, the hu-
man receptors for both Hep and HA are the same protein: 
HARE. Importantly, both activities are in the 190-HARE and 
315-HARE isoforms. Furthermore, we find that the Link do-
main of HARE is crucial for HA internalization, but is not re-
quired for Hep internalization (Figure 3B). We also find that 
HA and Hep can bind to HARE simultaneously; these re-
sults will be presented elsewhere in a more extensive analy-
sis of the HA and Hep binding sites of HARE, and their rela-
tionships with other ligands (E. N. Harris and P. H. Weigel, 
unpublished results).
Our published and unpublished results show that HS, in 
contrast to the more highly sulfated Hep, does not bind to 
HARE (23, 24). This is significant, because HSPGs are found 
throughout the developing hematopoietic system (68), and if 
HARE bound HSPGs, it might interfere with development 
of these cells in spleen and, possibly, bone marrow. Exclu-
sive binding of Hep, but not HSPG, by HARE could be ad-
vantageous in that by-products of coagulation and infection 
are readily cleared from the circulation, keeping the systemic 
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fluids relatively clear of these undesired products in contrast 
to their higher concentrations in wound or infected areas. 
For instance, tissue factor pathway inhibitor counteracts tis-
sue factor and inhibits factors VIIa and X (69). Under normal 
conditions, factor Xa, a proteolytic product of factor X, in the 
presence of factors VII and VIIIa, will bind tissue factor path-
way inhibitor on endothelial cells and be internalized via an 
unknown receptor (70). In the presence of Hep, however, tis-
sue factor pathway inhibitor binds Hep and is released from 
the endothelium to form complexes that can include factors 
VIIa and X (71). These complexes may then bind via the Hep, 
and be internalized and cleared from blood by cells express-
ing HARE. 
Based on the discovery that HARE mediates the rapid in-
ternalization of Hep, an intriguing possibility is that Hep 
may be the “vehicle” for the turnover of dozens of different 
Hep-binding proteins (e.g. growth factors) found in blood, 
lymph, and interstitial fluids. Hep-protein complexes in the 
vascular and lymphatic circulation systems could be cleared 
by HARE and degraded. Such a general clearance mecha-
nism might be more physiologically practical than the uti-
lization of dozens of different parallel receptor systems in 
which individual proteins in protein-Hep complexes were 
recognized and cleared from blood. 
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